To date, among the requests for medical help with headaches, a significant part of patients are people with paroxysmal headaches accompanied by pronounced autonomic disorders. This group of headaches belongs to terminal vegetative cephalgia and requires a new approach in therapy with the use of modern medications. The drug irinex (erenumab), used as a solution for subcutaneous administration, proved to be one of the most effective antimegrenous agents. Within the framework of this scientific work, the results of the use of the drug irinex in the treatment of cluster headaches and other trigeminal autonomic cephalgias were considered. The study used an indicator of the average monthly frequency of headaches in patients, as well as a subjective scale of severity of autonomic disorders. The drug Iirinex is a modern anti-migraine drug, used as a solution for subcutaneous administration and contains the active substance - erenumab. As a result of the study, there was a general decrease in the frequency of painful paroxysms for 6 months with regular use of the drug at a dosage of 140 mg and an increase in the level of physical activity of patients. Thus, the use of the drug irinex has shown high efficacy and safety in the treatment of cluster headaches and other trigeminal autonomic cephalgias.
1. Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34. doi:10.1186/s10194-022-01402-2
2. Burish M. Cluster Headache and Other Trigeminal Autonomic Cephalalgias. Continuum (Minneap Minn). 2018;24(4, Headache):1137-56. doi:10.1212/CON.0000000000000625
3. Eller M, Goadsby PJ. Trigeminal autonomic cephalalgias. Oral Dis. 2016;22(1):1-8. doi:10.1111/odi.12263
4. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202
5. Boes CJ, Capobianco DJ, Matharu MS, Goadsby PJ. Wilfred Harris' early description of cluster headache. Cephalalgia. 2002;22(4):320-6. doi:10.1046/j.1468-2982.2002.00360.x
6. Worm J, Falkenberg K, Olesen J. Histamine and migraine revisited: mechanisms and possible drug targets. J Headache Pain. 2019;20(1):30. doi:10.1186/s10194-019-0984-1
7. Leone M, Ferraro S, Proietti Cecchini A. The neurobiology of cluster headache. Handb Clin Neurol. 2021;182:401-14. doi:10.1016/B978-0-12-819973-2.00027-7
8. Reinisch VM, Schankin CJ, Felbinger J, Sostak P, Straube A. Headache in the elderly. Schmerz. 2008;22 Suppl 1:22-30. [in German]. doi:10.1007/s00482-007-0609-5
9. Bahra A, Evans RW. The Secondary Headaches. Cephalalgia. 2021;41(4):427-30. doi:10.1177/0333102421999996
10. Hinge MA, Patel D, Shah M. Simultaneous evaluation of amlodipine besylate and candesartan cilexetil by applying chemometric assisted spectrophotometric method. Pharmacophore. 2022;13(1):1-9.
11. Cicalău GI, Miere F, Mandal AK, Ganea M, Scrobota I, Ciavoi G, et al. Formulation and Characterization of Hydrophilic Ointment Bases with Carvacrol and Magnolol for Periodontal Application. Pharmacophore. 2022;13(2):26-32.
12. Mier RW, Dhadwal S. Primary Headaches. Dent Clin North Am. 2018;62(4):611-28. doi:10.1016/j.cden.2018.06.006
13. Weaver-Agostoni J. Cluster headache. Am Fam Physician. 2013;88(2):122-8.
14. Mathew NT. Cluster headache. Semin Neurol. 1997;17(4):313-23. doi:10.1055/s-2008-1040944
15. Sumantri AF, Bashari MH, Tadjoedin H, Atik N. Risk of coronavirus disease 2019 (COVID-19) infection on leukemia patients: basic science to clinical aspect. J Adv Pharm Educ Res. 2022;12(1):38-45.
16. Xuan EY, Razak NF, Ali AM, Said MM. Evaluation of knowledge, attitudes, and perceptions on halal pharmaceuticals among pharmacy students from Malaysian private universities. J Adv Pharm Educ Res. 2022;12(1):84-90.
17. Bhardwaj M, Kapila R, Neha A, Jain R, Mittal P, Suri M. Awareness, Perceived Risk, and Protective Behavior Towards Covid-19 Among Undergraduate Students of Delhi and NCR, India. Int J Pharm Res Allied Sci. 2022;11(3):71-80.
18. Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJ, et al. European Headache Federation; Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide; World Health Organization. European principles of management of common headache disorders in primary care. J Headache Pain. 2007;8 Suppl 1:S3-47. doi:10.1007/s10194-007-0366-y
19. LiverTox L. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Migraine Headache Agents. 2021 Jul 22.
20. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377(22):2123-32. doi:10.1056/NEJMoa1705848
21. Datta A, Gupta S, Maryala S, Aggarwal V, Chopra P, Jain S. Erenumab for episodic migraine. Pain Manag. 2022;12(5):587-94. doi:10.2217/pmt-2021-0077
22. Rzhepakovsky IV, Areshidze DA, Avanesyan SS, Grimm WD, Filatova NV, Kalinin AV, et al. Phytochemical Characterization, Antioxidant Activity, and Cytotoxicity of Methanolic Leaf Extract of Chlorophytum Comosum (Green Type) (Thunb.) Jacq. Molecules. 2022;27(3):762. doi:10.3390/molecules27030762
23. Edvinsson L. Role of CGRP in Migraine. Handb Exp Pharmacol. 2019;255:121-30. doi:10.1007/1642018201
24. Maslova AY, Tskaeva AA, Ashurova ZA, Abazova A, Ismailov MM, Ismailova MM. Study of the Effect of Baricitinib on the Course of COVID-19. J Pharm Res Int. 2021;33(35):204-13.
25. Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP, and Erenumab Treatment Response: Towards Precision Medicine in Migraine. Ann Neurol. 2022;92(5):846-59. doi:10.1002/ana.26472
Copyright © 2024 - All Rights Reserved - Archives of Pharmacy Practice
Developed by Archives of Pharmacy Practice
